Welcome to HitGen
CN EN

Pipeline

HitGen is focusing our innovative ability on discovering novel therapies that will make a real difference to patients with cancer or Inflammatory diseases. We have developed a broad and deep pipeline of both wholly owned and partnered therapeutics candidates. Our pipeline includes both small molecule and nucleic acid drug drugs.

Small molecule drug pipeline

Oncology
Projects
Indication
Hit Optimization
Lead Optimization
Preclinical Study
IND Filing
Clinical Trails
HG146

Class I/IIb selective HDAC inhibitor, capsule

Multiple myeloma
HG146

Class I/IIb selective HDAC inhibitor, capsule

Solid tumor
HG030

2nd generation NTRK/ROS1 inhibitor, tablet

Solid tumor
HG381

2nd generation STING agonist, iv

Cancer
HG153

Menin-MLL, tablet

MLL-r or NPM1mu AML/ALL
HG248

PROTAC

Cancer
Inflammation
HGP0508

Small molecule inhibitor for IL-17a, po

Inflammation
Others
HGP1069

ROCK2 inhibitor,eye drop

Glaucoma

Thanks for reading!

For more details on how we can advance your innovative drug discovery projects
验证码
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information

XML 地图 | Sitemap 地图

欧洲杯竞猜官方平台